Drugs Made In America Acquisition Corp.
DMAA
$10.54
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 692.38% | 99.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 692.38% | 99.92% | |||
| Operating Income | -692.38% | -99.92% | |||
| Income Before Tax | -90.25% | -4.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -90.25% | -4.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -90.25% | -4.54% | |||
| EBIT | -692.38% | -99.92% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -90.49% | -4.54% | |||
| Normalized Basic EPS | -90.42% | -4.68% | |||
| EPS Diluted | -90.49% | -4.54% | |||
| Normalized Diluted EPS | -90.42% | -4.68% | |||
| Average Basic Shares Outstanding | 2.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 2.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||